Reyvow

Active Ingredient(s): Lasmiditan Succinate
FDA Approved: * October 11, 2019
Pharm Company: * ELI LILLY AND CO
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Reyvow Overview

Lasmiditan, sold under the trade name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.[1] It is not useful for prevention.[1] It is taken by mouth.[1] Common side effects include sleepiness, dizziness, tiredness, and numbness.[1] It is a "neurally acting anti-migraine agent" ditan. Lasmiditan was approved in the Un...

Read more Reyvow Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lasmiditan

Recent Reyvow Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lasmiditan Succinate
  • Tablet: 100mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lasmiditan Succinate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 January 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA